JP2022506110A5 - - Google Patents
Info
- Publication number
- JP2022506110A5 JP2022506110A5 JP2021523278A JP2021523278A JP2022506110A5 JP 2022506110 A5 JP2022506110 A5 JP 2022506110A5 JP 2021523278 A JP2021523278 A JP 2021523278A JP 2021523278 A JP2021523278 A JP 2021523278A JP 2022506110 A5 JP2022506110 A5 JP 2022506110A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutically acceptable
- solvate
- hydrate
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185222A JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752503P | 2018-10-30 | 2018-10-30 | |
| US62/752,503 | 2018-10-30 | ||
| PCT/US2019/058896 WO2020092592A1 (en) | 2018-10-30 | 2019-10-30 | Therapeutic compounds and compositions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185222A Division JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022506110A JP2022506110A (ja) | 2022-01-17 |
| JP2022506110A5 true JP2022506110A5 (enExample) | 2022-10-28 |
Family
ID=70464752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021523278A Pending JP2022506110A (ja) | 2018-10-30 | 2019-10-30 | 治療用化合物および組成物 |
| JP2024185222A Pending JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185222A Pending JP2025011310A (ja) | 2018-10-30 | 2024-10-21 | 治療用化合物および組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210261524A1 (enExample) |
| EP (1) | EP3873444A4 (enExample) |
| JP (2) | JP2022506110A (enExample) |
| KR (1) | KR20210087467A (enExample) |
| CN (1) | CN112996495A (enExample) |
| AU (1) | AU2019373237A1 (enExample) |
| BR (1) | BR112021008345A2 (enExample) |
| CA (1) | CA3117470A1 (enExample) |
| IL (1) | IL282766A (enExample) |
| WO (1) | WO2020092592A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2733405C2 (ru) | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| CA3089970A1 (en) | 2018-02-07 | 2019-08-15 | eXIthera Pharmaceuticals Inc. | Therapeutic compounds and compositions |
| CN113056263A (zh) * | 2018-10-30 | 2021-06-29 | 艾克赛特赫拉制药有限责任公司 | 治疗化合物和组合物 |
| CN116782911A (zh) * | 2020-09-17 | 2023-09-19 | 艾克赛特赫拉制药有限责任公司 | 治疗性化合物、组合物及其使用方法 |
| CA3192119A1 (en) * | 2020-09-17 | 2022-03-24 | Neil J. Hayward | Therapeutic compounds, compositions, and methods of use thereof |
| TW202346278A (zh) * | 2022-03-28 | 2023-12-01 | 大陸商四川海思科製藥有限公司 | 2-氨基吡啶衍生物製備方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9802206D0 (sv) * | 1998-06-22 | 1998-06-22 | Astra Pharma Inc | Novel compounds |
| EP1871741A4 (en) * | 2005-04-04 | 2012-01-11 | Daiamed Inc | SUBSTITUTED AZETIDINONE |
| US8343999B2 (en) * | 2007-04-10 | 2013-01-01 | Bristol-Myers Squibb Company | Thiazolyl compounds useful as kinase inhibitors |
| JP6033319B2 (ja) * | 2011-10-14 | 2016-11-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 第ＸＩａ因子阻害剤としての置換テトラヒドロイソキノリン化合物 |
| RU2733405C2 (ru) * | 2014-02-07 | 2020-10-01 | Экзитера Фармасьютикалз Инк. | Терапевтические соединения и композиции |
| US20190315711A1 (en) * | 2016-12-23 | 2019-10-17 | Exithera Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
-
2019
- 2019-10-30 JP JP2021523278A patent/JP2022506110A/ja active Pending
- 2019-10-30 EP EP19877575.1A patent/EP3873444A4/en active Pending
- 2019-10-30 WO PCT/US2019/058896 patent/WO2020092592A1/en not_active Ceased
- 2019-10-30 CA CA3117470A patent/CA3117470A1/en active Pending
- 2019-10-30 KR KR1020217014647A patent/KR20210087467A/ko not_active Withdrawn
- 2019-10-30 AU AU2019373237A patent/AU2019373237A1/en not_active Abandoned
- 2019-10-30 BR BR112021008345-6A patent/BR112021008345A2/pt unknown
- 2019-10-30 CN CN201980072037.6A patent/CN112996495A/zh active Pending
-
2021
- 2021-04-28 IL IL282766A patent/IL282766A/en unknown
- 2021-04-28 US US17/243,120 patent/US20210261524A1/en not_active Abandoned
-
2024
- 2024-10-21 JP JP2024185222A patent/JP2025011310A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022506110A5 (enExample) | ||
| Gimson et al. | Earlier charcoal haemoperfusion in fulminant hepatic failure | |
| JP2022523712A5 (enExample) | ||
| Donckerwolcke et al. | Hemodialysis in infants and small children | |
| JP2022506109A5 (enExample) | ||
| JP2014500280A5 (enExample) | ||
| Nicolau et al. | Myoglobin clearance during continuous veno-venous hemofiltration with or without dialysis | |
| Buchanan | Sulphamethoxazole, hypoalbuminaemia, crystalluria, and renal failure | |
| Heney et al. | Continuous arteriovenous haemofiltration in the treatment of tumour lysis syndrome | |
| McClelland et al. | Multiple organ failure—a role for plasma exchange? | |
| Heath et al. | Treatment of antidepressant poisoning with resin hemoperfusion | |
| Gaynor | Use of modified ultrafiltration after repair of congenital heart defects | |
| Björkman et al. | Pharmacokinetics of quinacrine after intrapleural instillation in rabbits and man | |
| RU2021115308A (ru) | Терапевтические соединения и композиции | |
| Clar et al. | Hemofiltration: determinants of drug loss and concentration | |
| Nixon et al. | Cardiogenic shock treated with infusion of dextrose solution | |
| Dorsey | Venoarterial bypass in hypothermia | |
| CN102205115B (zh) | 乌司他丁作为急腹症引起的中毒性休克的抢救辅助药物的用途 | |
| RU2021115313A (ru) | Терапевтические соединения и композиция | |
| Caruso et al. | Continuous hemodialysis for the management of acute renal failure in the presence of cerebellar hemorrhage: case report | |
| WO1996037205A1 (en) | Remedy for endotoxinemia and multiple organ failure induced thereby | |
| Balazs et al. | Comparison of effects of quinidine and dihydroquinidine on canine heart | |
| Crerar-Gilbert et al. | Use of inhaled nitric oxide in pulmonary embolism | |
| Heath et al. | Resin hemoperfusion in chloroquine poisoning | |
| Marshall | Tricyclic overdose |